Against the Odds: The Story of AIDS Drug Development, Politics and Profits Book

	Acknowledgments
	Introduction
	Cast of Characters
1	Unlikely Heroes	1
2	A New Virus: The Search for Magic Bullets	10
3	The FDA and the Public Interest	22
4	The AZT Breakthrough	37
5	Placebos and Profiteering	48
6	The Rise of the AIDS Underground	60
7	Activism, ACT UP, and Dextran Sulfate	71
8	The Pentamidine Saga	83
9	Loosening the Regulatory Leash	97
10	Grassroots Trials Come of Age: Activists Seizing Control	110
11	Business as Usual: The Patenting and Pricing of AZT	125
12	On the Defensive: Pentamidine Profits and a Corporation Under Siege	142
13	Absence of Vision: The Ganciclovir Scandal	157
14	Parallel Track and the Promise of ddI	172
15	Research on Trial: The Limits of the Government System	186
16	AIDS and Women, Children, and Minorities	198
17	The Illicit Compound Q Trials	207
18	The ddI Milestone	216
19	Crashing the Gates: Activists Enter the Drug Testing Sanctum	225
	Conclusion	236
	Appendix A: Milestones in AIDS Drug Development	247
	Appendix B: How a Clinical Trial Is Designed	261
	Appendix C: The Challenge to the AZT Patent	267
	Sources	273
	Index	303